GlassScriptPhysician profile
Theodore S Grabow
NPI 1083647259
$1,872.99
in general payments reported to CMS, 2019-2025
25 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $208 · 2021: $16.09 · 2023: $280 · 2024: $400 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $355.53 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $156.74 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Vertos Medical, INC. | $142.52 | 2020-2024 | Mild Device Kit |
| Amgen INC. | $139.52 | 2019 | |
| Saluda Medical Americas, INC. | $106.05 | 2024 | Evoke |
| Scilex Pharmaceuticals INC. | $103.25 | 2019-2020 | |
| Averitas Pharma INC. | $101.11 | 2023 | Qutenza |
| Mdd US Operations, LLC | $99.72 | 2019-2020 | |
| Daiichi Sankyo INC. | $96.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $66.62 | 2019-2020 | |
| Lilly USA, LLC | $61.08 | 2019 | |
| Abbott Laboratories | $60.78 | 2019-2024 | Proclaim |
| Fidia Pharma USA INC. | $60.19 | 2019-2024 | Hyalgan, Triluron, Hymovis |
| Nevro Corp. | $51.83 | 2019-2023 | Senza |
| Upsher-Smith Laboratories LLC | $45.65 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.75 | 2020-2025 | Relistor |
| Pacira Therapeutics, INC. | $30.95 | 2019 | |
| Electronic Waveform Lab, INC. | $29.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $21.32 | 2019 | |
| Mml US, INC. | $20.58 | 2023 | Reactiv8 |
| Abbvie INC. | $18.20 | 2025 | |
| Kaleo, INC. | $17.90 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.34 | 2019 | |
| Shionogi INC | $14.76 | 2019 | |
| International Rehabilitative Sciences, INC | $14.74 | 2024 | Rs 4i Plus Sequential Stimulator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Grabow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.